Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials

@inproceedings{Maio2012PotentialityAB,
  title={Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials},
  author={Massimo Di Maio and G. Romano Daniele and Maria Carmela Piccirillo and Pasqualina Giordano and Giuseppe Signoriello and B. Galindo Daniele and Francesco Perrone},
  booktitle={Cancers},
  year={2012}
}
No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced HCC and well-preserved liver function, whilst the evidence about its effectiveness in patients with more severe liver impairment is less robust. A randomized trial to demonstrate the efficacy of… CONTINUE READING

Similar Papers

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 40 REFERENCES

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 1 EXCERPT